April 4, 2017 / 11:17 AM / 8 months ago

BRIEF-VBL Therapeutics presents data on immuno-oncology drug

April 4 (Reuters) - Vascular Biogenics Ltd-

* VBL Therapeutics presents data on mospd2, a novel immuno-oncology target

* Vascular Biogenics Ltd - study observed from clinical biopsies that mospd2 is prevalent in invasive human breast cancer tissue

* Vascular Biogenics Ltd - study observed from clinical biopsies that levels of mospd2 correlate to breast cancer invasiveness

* Vascular Biogenics - it was further observed that knockdown of mospd2 in human breast cancer cell line using crispr technology led to blockade of egf signaling

* Vascular Biogenics Ltd -mospd2 knockdown using crispr technology led to significant reduction of breast cancer cell migration in vitro, metastasis in mouse model

* Vascular Biogenics Ltd - “believe that mospd2 may be involved in regulation of cell motility in addition to breast cancer” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below